Byvasda (bevacizumab biosimilar)

Update of ORIENT-31 trial of sintilimab (PD1) in #EGFR NSCLC @LancetRespirMed. Adding sintilimab to chemo improved PFS (HR 0.72) over chemo alone but not as much as triplet of sintilimab + IBI305 (VEGF) + chemo with PFS (HR 0.51). Similar OS across arms. https://t.co/KYtK67XtqL (@StephenVLiu)

A four-drug regimen — sintilimab, IBI305, pemetrexed, and cisplatin — improved survival in patients with EGFR-mutated non–small-cell lung cancer, with no new safety signals, a new study found. https://t.co/sqhNJEmeod #LungCancer @JPatelMD (@JWatch)

Dr. Shun Lu presents update of ORIENT-31: sintilimab +/- IBI305 + chemo in #EGFR mutant NSCLC post TKI therapy. Three arm study: chemo vs chemo + sintilimab vs chemo + sintilimab + IBI305 (angiogenesis). #ESMO22 (@StephenVLiu)

Results from ORIENT-31 @TheLancetOncol. 444 pts with #EGFR mutant NSCLC post TKI randomized to cisplatin + pemetrexed alone or with sintilimab+/- IBI305 (anti-VEGF). Adding sintilimab + IBI305 sig improved PFS (6.9 vs 4.3m, HR 0.46). Other data pending. https://t.co/rXBZ1zDeOx (@StephenVLiu)

Abstract for the ORIENT-31 trial @Annals_Oncology. This phase III showed PFS benefit with adding sintilimab (PDL1) and IBI305 (VEGF) to cis/pem in #EGFR mutant NSCLC. Await results from third arm (cis/pem + sintilimab) for comparison. #ESMOVirtualPlenary https://t.co/zZYreBHGY7 (@StephenVLiu)

Pts with advanced #EGFR mutant NSCLC post-TKI were randomized to chemo (cis/pem + pem maintenance) + placebo, chemo + anti-PDL1 (sintilimab), or chemo + PDL1 + VEGF (IBI305, bevacizumab biosimilar). Conditional crossover from chemo to sintilimab allowed. @OncoAlert @myESMO (@StephenVLiu)

Impressive PFS benefit. In #EGFR mutant NSCLC post TKI, cis/pem plus PDL1+VEGF (sintilimab+IBI305) significantly improved PFS over cis/pem + placebos (HR 0.46). Curves split early, mPFS 6.9 vs 4.3m. #LCSM #ESMOasiaweek21 @myESMO (@StephenVLiu)

Immunotherapy in #EGFR NSCLC was the focus of the #ESMOVirtualPlenary. Dr. Shun Lu presents the first interim analysis of the ORIENT-31 trial: phase III trial of cis/pem vs cis/pem + sintilimab (PDL1) vs cis/pem + sintilimab + IBI305 (bevacizumab biosimilar) #ESMOasiaweek21 #LCSM (@StephenVLiu)

EGFRmut NSCLC post TKI: Quadriplet CT-IO-antiangiogenic [pemetrexed+cisplatin+Sintilimab (aPD-1 Ab)+IBI305 (bevacizumab biosimilar)] increases efficacy over CT. Activity against CT-IO not reported. No PD-L1 data presented. Confirms the IMpower150 results. #ESMOasiaweek21 (@BenjaminBesseMD)